Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Hydromorphone vs Oral Morphine for Breakthrough Cancer Pain
NCT00125801Phase 3Terminated
- Sponsor
- Erasmus MC
- Start
- Aug 2005
- Primary completion
- May 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydromorphone in breakthrough cancer pain (BTcP) (2 arms), sponsored by Erasmus MC. Primary endpoint: Pain Intensity Difference at 15 months. Started Aug 2005; status: terminated.
02
Drugs
hydromorphone
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT00125801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125801.